YH002 / Biocytogen, Syncromune - LARVOL DELTA

A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=6 | Completed | Sponsor: Eucure (Beijing) Biopharma Co., Ltd | Recruiting ➔ Completed | N=44 ➔ 6

Enrollment change • Trial completion • Oncology • Solid Tumor

BIO-Europe Spring 2024 | BIOcyto invites you for a 1-on-1 appointment [Google translation] (Biocytogen Press Release) - "Biocytogen's Antibody Drug Business (BDL) team will participate in the BIO-Europe Spring conference to be held in Barcelona, ​​Spain, from March 18 to 20, 2024, and participate in 1-on-1 appointments and exchanges...Antibodies and antibody-like molecules available for cooperation include: 40+ PCC stage antibody molecules: B7-H3, Siglec-15, TNFR2, MUC16, NKG2D, ROR1, TIGIT, IL-2RA, AMHR2, CD73, CD40 (antagonist) antibodies, etc...60+ fully human GPCR single/double antibody projects: CCR8, GPRC5D, LGR5, CCR2, etc...The five clinical-stage antibody molecules available for collaboration are: YH008...YH003 (CD40 agonist monoclonal antibody)...YH001 (CTLA-4 monoclonal antibody)...YH002...YH004 (4-1BB monoclonal antibody)....The antibody molecules in Biocytogen's antibody library can be directly provided to global pharmaceutical companies and biotechnology companies for evaluation and licensing cooperation."

Licensing / partnership • Hematological Malignancies • Melanoma • Mucosal Melanoma • Oncology • Sarcoma • Skin Cancer • Soft Tissue Sarcoma • Solid Tumor

Biocytogen - Eucure and Syncromune Establish Technology Transfer Agreement for YH002 and Multiple Other Clinical-Stage Antibodies (Market Screener) - "Eucure (Beijing) Biopharma Co., Ltd...a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd...announced today that the company has entered into a technology transfer agreement with Syncromune, Inc....Under the newly signed agreement, Syncromune will be granted an option right and upon option-exercise, Eucure will transfer technology to Syncromune for the manufacture of YH002 and other clinical-stage antibodies currently being evaluated for intratumoral immunotherapy based on SYNC-T technology. Under the newly signed agreement, Syncromune will pay Eucure an upfront fee and, upon option-exercise, Eucure is entitled to receive milestone fees."

Licensing / partnership • Oncology • Solid Tumor

Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy (Businesswire) - "Eucure (Beijing) Biopharma...announced today that the company has entered into a worldwide licensing agreement with Syncromune...for the development and commercialization of intratumoral immunotherapies along with Syncromune’s Syncrovax™ technology. Under the terms of the agreement, Syncromune will acquire exclusive worldwide rights for development and commercialization of the intratumoral combination therapy containing Eucure’s YH002, and multiple other active ingredients as part of the Syncrovax™ therapy. Eucure/Biocytogen reserve all the global rights beyond Syncrovax™....Eucure will be responsible for drug manufacturing and supply, and Syncromune will be responsible for clinical development and commercialization."

Licensing / partnership • Oncology • Solid Tumor

"Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy https://t.co/a11tpeUXr5" (@NewsFromBW)

Oncology

YH002002: A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies (clinicaltrials.gov) - P1 | N=15 | Completed | Sponsor: Eucure (Beijing) Biopharma Co., Ltd | Recruiting ➔ Completed | N=48 ➔ 15 | Trial completion date: Jul 2023 ➔ Nov 2021 | Trial primary completion date: Jul 2023 ➔ Sep 2021

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study to Assess YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=44 | Recruiting | Sponsor: Eucure (Beijing) Biopharma Co., Ltd | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Oncology • Solid Tumor

Biocytogen Subsidiary, Eucure Biopharma, Announces the First Patient Dosing for a Phase I Multi-regional Clinical Trial of YH002 (Anti-OX40 mAb) in Combination with YH001 (Anti-CTLA-4 mAb) in Australia (Canada Newswire) - "Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I multi-regional clinical trial (MRCT) of YH002 (anti-OX40 monoclonal antibody, mAb) in combination with YH001 (anti-CTLA-4 mAb) (No. YH002004) in Australia. This phase I MRCT will be conducted in Australia and China. The clinical trial is an open-label, dose-escalation phase I study designed to evaluate the safety, tolerability and preliminary efficacy of YH002 in combination with YH001 in patients with advanced solid tumors."

Trial status • Oncology • Solid Tumor

A Study to Assess YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - P1; N=44; Not yet recruiting; Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Clinical • Combination therapy • New P1 trial • Oncology • Solid Tumor

[VIRTUAL] A first-in-human phase dose-escalation study of YH002, a recombinant humanized agonistic anti-OX40 IgG1 monoclonal antibody, in patients with advanced solid tumors. (ASCO 2021) - P1 | "These preliminary results demonstrate that YH002 was safe and tolerable up to 0.3mg/kg . Updated safety and antitumor activity will be presented."

Clinical • P1 data • Bladder Cancer • Breast Cancer • Colon Cancer • Colorectal Cancer • Dermatology • Fatigue • Gastrointestinal Cancer • Genito-urinary Cancer • Musculoskeletal Pain • Oncology • Pain • Pneumonia • Prostate Cancer • Pruritus • Solid Tumor • Thymus Cancer • Urothelial Cancer

A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Eucure (Beijing) Biopharma Co., Ltd; Trial primary completion date: Mar 2021 ➔ Jul 2023

Clinical • Trial primary completion date • Oncology • Solid Tumor

Comparative Methylome Analysis of Campylobacter jejuni Strain YH002 Reveals a Putative Novel Motif and Diverse Epigenetic Regulations of Virulence Genes. (PubMed, Front Microbiol) - "Additional investigations into the existence of DNA methylation sites within gene promoters, which may ultimately result in altered levels of transcription, revealed several virulence genes putatively regulated using this mode of action. Of those identified, a flagella gene (flhB), a RNA polymerase sigma factor (rpoN), a capsular polysaccharide export protein (kpsD), and a multidrug efflux pump were highly notable."

Journal • Gastroenterology • Gastrointestinal Disorder

A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Eucure (Beijing) Biopharma Co., Ltd; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Oncology • Solid Tumor

[VIRTUAL] Rapid screening of novel OX40 agonistic antibodies for cancer immunotherapy (AACR-II 2020) - "Furthermore, we showed that YH002 works in concert with Pembrolizumab in double humanized model of h-OX40 and h-PD1. The combination of YH002 and ipilimumab is synergistic in double humanized model of h-OX40 and h-CTLA4. In the GLP-compliant single-dose toxicology study, the MTD of a single i.v. dose of YH002 in cynomolgus monkeys was considered to be 200 mg/kg/day. Repeated i.v. infusions of YH002 to male and female cynomolgus monkeys at 10, 30, or 90 mg/kg for 29 days (QW×5) were tolerated, the HNSTD was considered to be 90 mg/kg."

Oncology • PD-1 • TNFA

A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Clinical • New P1 trial • Oncology • Solid Tumor